XOSPATA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation when the disease has come back or has not …

2021年03月31日讯 / 生物谷 BIOON/ --安斯泰来（Astellas）近日宣布，比较靶向抗癌药Xospata（适加坦®，通用名：吉瑞替尼，gilteritinib）与化疗治疗复发（疾病复发）或难治 …

2024年9月30日 · Xospata (gilteritinib) is given as an oral tablet once daily, with or without food, in adults for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation (as …

Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug. [7] Gilteritinib acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor. [8] Gilteritinib was developed by …

XOSPATA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a FLT3 mutation when the disease has come back or has not improved after previous …

xospata（富马酸吉瑞替尼片，Gilteritinib，以下统称为吉瑞替尼） 2021年1月30日，中国国家药品监督管理局（NMPA）正式宣布适加坦®（富马酸吉瑞替尼片，Gilteritinib，以下统称为吉瑞替 …

2019年9月20日 · Xospata is a cancer medicine used to treat adults with acute myeloid leukaemia (AML), a cancer of white blood cells. Xospata is used when AML has either come back or has …

XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA …

2022年1月1日 · 1.1 Relapsed or Refractory Acute Myeloid Leukemia - XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) …

XOSPATA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) who have a FMS-like tyrosine kinase 3 (FLT3) mutation: • when the disease has come back, or